DE69033631T2 - Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon - Google Patents
Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davonInfo
- Publication number
- DE69033631T2 DE69033631T2 DE69033631T DE69033631T DE69033631T2 DE 69033631 T2 DE69033631 T2 DE 69033631T2 DE 69033631 T DE69033631 T DE 69033631T DE 69033631 T DE69033631 T DE 69033631T DE 69033631 T2 DE69033631 T2 DE 69033631T2
- Authority
- DE
- Germany
- Prior art keywords
- monoclonal antibody
- hypervariable region
- constructs
- therapeutic use
- radioisotope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45091889A | 1989-12-14 | 1989-12-14 | |
PCT/US1990/007436 WO1991009058A1 (en) | 1989-12-14 | 1990-12-14 | Therapeutic uses of the hypervariable region of monoclonal antibody m195 and constructs thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69033631D1 DE69033631D1 (de) | 2000-10-26 |
DE69033631T2 true DE69033631T2 (de) | 2001-05-17 |
Family
ID=23790050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69033631T Expired - Lifetime DE69033631T2 (de) | 1989-12-14 | 1990-12-14 | Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon |
Country Status (9)
Country | Link |
---|---|
US (1) | US5730982A (de) |
EP (1) | EP0504327B1 (de) |
JP (1) | JPH05503632A (de) |
AT (1) | ATE196477T1 (de) |
AU (1) | AU659083B2 (de) |
CA (1) | CA2072017A1 (de) |
DE (1) | DE69033631T2 (de) |
ES (1) | ES2152216T3 (de) |
WO (1) | WO1991009058A1 (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776093A (en) * | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US6599505B1 (en) * | 1992-04-10 | 2003-07-29 | Research Development Foundation | Immunotoxins directed against CD33 related surface antigens |
ZA932523B (en) * | 1992-04-10 | 1994-10-08 | Res Dev Foundation | Immunotoxins directed against cd33 related surface antigens |
WO1994007138A1 (en) | 1992-09-14 | 1994-03-31 | Fodstad Oystein | Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations |
NO180658C (no) | 1994-03-10 | 1997-05-21 | Oeystein Fodstad | Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner |
NO961031D0 (no) * | 1996-03-13 | 1996-03-13 | Det Norske Radiumshospital Tum | Fremgangsmåte til å drepe uönskede målceller |
US20060073133A1 (en) * | 1997-04-02 | 2006-04-06 | Kikly Kristine K | Sialoadhesin factor-3 antibodies |
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
US7736651B1 (en) | 2000-11-24 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Alpha emitting constructs and uses thereof |
CA2333125C (en) * | 1998-05-26 | 2009-12-15 | Sloan-Kettering Institute For Cancer Research | Alpha emitting constructs and uses thereof |
IT1307826B1 (it) * | 1999-12-16 | 2001-11-19 | Dipartimento Di Medicina Speri | Metodo diagnostico per il riconoscimento di cellule mieloidi normali eleucemiche, ligandi utilizzati in detto metodo e formulazioni ad uso |
AU2003285878B2 (en) | 2002-11-07 | 2011-04-28 | Immunogen, Inc. | Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same |
WO2008030538A2 (en) * | 2006-09-07 | 2008-03-13 | Stemline Therapeutics, Inc. | Cancer stem cell-targeted cancer therapy |
JP2010509234A (ja) * | 2006-11-02 | 2010-03-25 | シアトル ジェネティックス, インコーポレイテッド | 新生物疾患、自己免疫疾患および炎症性疾患を処置する方法 |
DE102009045006A1 (de) | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
WO2016201389A2 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
CA2988982A1 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
KR20200033798A (ko) | 2017-08-03 | 2020-03-30 | 알렉터 엘엘씨 | 항-cd33 항체 및 이의 이용 방법 |
WO2019113041A1 (en) * | 2017-12-04 | 2019-06-13 | Actinum Pharmaceuticals, Inc. | Methods for treatment of patients with myelodyplastic syndromes |
SG11202101552SA (en) | 2018-08-31 | 2021-03-30 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
US11666672B2 (en) | 2018-11-21 | 2023-06-06 | City Of Hope | Anti-CD33 antibody-guided imaging and treatment of acute myeloid leukemia |
WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
-
1990
- 1990-12-14 JP JP91504637A patent/JPH05503632A/ja active Pending
- 1990-12-14 AU AU73135/91A patent/AU659083B2/en not_active Expired
- 1990-12-14 WO PCT/US1990/007436 patent/WO1991009058A1/en active IP Right Grant
- 1990-12-14 AT AT91904912T patent/ATE196477T1/de not_active IP Right Cessation
- 1990-12-14 CA CA002072017A patent/CA2072017A1/en not_active Abandoned
- 1990-12-14 EP EP91904912A patent/EP0504327B1/de not_active Expired - Lifetime
- 1990-12-14 DE DE69033631T patent/DE69033631T2/de not_active Expired - Lifetime
- 1990-12-14 ES ES91904912T patent/ES2152216T3/es not_active Expired - Lifetime
-
1995
- 1995-02-02 US US08/383,615 patent/US5730982A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP0504327B1 (de) | 2000-09-20 |
US5730982A (en) | 1998-03-24 |
AU7313591A (en) | 1991-07-18 |
CA2072017A1 (en) | 1991-06-15 |
ES2152216T3 (es) | 2001-02-01 |
EP0504327A4 (en) | 1993-06-30 |
EP0504327A1 (de) | 1992-09-23 |
ATE196477T1 (de) | 2000-10-15 |
DE69033631D1 (de) | 2000-10-26 |
WO1991009058A1 (en) | 1991-06-27 |
JPH05503632A (ja) | 1993-06-17 |
AU659083B2 (en) | 1995-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69033631T2 (de) | Therapeutische verwendungen der hypervariablen region des monoklonalen antikörpers m195 und konstrukte davon | |
DE68915812T2 (de) | Funktionspezifische Antikörper. | |
ATE46084T1 (de) | Immunotoxin-konjugate. | |
DE69729283D1 (de) | GLYKOSYLIERTE IgG ANTIKÖRPER | |
DE69429095D1 (de) | Humanisierte antikoerper | |
LU91271I2 (fr) | Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI) | |
DE68929384D1 (de) | Therapeutische Zusammensetzungen die monoklonale Antikörper enthalten gegen den menschlichen Rezeptor für epidermalen Wachstumsfaktor | |
NO910923D0 (no) | Trifunksjonell antistofflignende forbindelse som et kombinert diagnostisk og terapeutisk middel. | |
DE68912334T2 (de) | Immunokonjugate für krebs-diagnose und -therapie. | |
EP0141079A3 (en) | Monoclonal antibodies specific for membrane-associated antigens | |
CA2093928A1 (en) | Monoclonal antibodies for detection and treatment of cancer | |
ATE79038T1 (de) | Anti-immuntoxine gegen menschlichen eierstockkrebs und verfahren zu deren verwendung. | |
OA04205A (fr) | L'exclusion (anti-aliasing) des fréquences spatiales au moyen du placement de geophones et de sources. | |
DE69125485T2 (de) | Verfahren und zwischenprodukte synthetischer antikörperderivate | |
IT7927258A0 (it) | Procedimento di deposizione chimica di oro per riduzione autocatalitica. | |
IT8024223A0 (it) | Procedimento di valorizzazione difrazioni c4 olefiniche. | |
DE69129109D1 (de) | Antikörperkonjugate für die behandlung neoplastischer krankheiten | |
FI853389L (fi) | Tumoerlaekemedel och foerfarande foer dess framstaellning. | |
RS49734B (sr) | Primena intravenoznih kontrastnih sredstava za projekcionu mamografiju | |
ES2121881T3 (es) | Anticuerpos monoclonales anti-gangliosidos, su preparacion y su empleo como agente terapeutico de tumores. | |
DE69527868D1 (de) | Monoklonaler Antikörper gegen den tumorzytotoxischen Faktor II (TCF-II) | |
IT8022825A0 (it) | Agenti terapeutici piridilammino triazolici. | |
EP0446797A3 (en) | Synthetic peptides containing factor viia sequences and their use | |
FI953708A0 (fi) | Menetelmä terapeuttisesti aktiivisten makrosyklisten bifunktionaalisten kelaatinmuodostajien, niiden kompleksien sekä niiden vasta-ainekonjugaattien valmistamiseksi | |
NO862346D0 (no) | Fremgangmsaate og maskin for tilsetting av farvemidler til malinger og fernisser. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |